Growth Metrics

TherapeuticsMD (TXMD) Short term Debt (2021 - 2022)

TherapeuticsMD (TXMD) has disclosed Short term Debt for 3 consecutive years, with $93.6 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Short term Debt rose 524.01% year-over-year to $93.6 million, compared with a TTM value of $93.6 million through Sep 2022, up 524.01%, and an annual FY2021 reading of $188.3 million, changed N/A over the prior year.
  • Short term Debt was $93.6 million for Q3 2022 at TherapeuticsMD, up from $90.8 million in the prior quarter.
  • Across five years, Short term Debt topped out at $202.9 million in Q1 2022 and bottomed at $5.0 million in Q1 2021.